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Abstract
Direct drug screening against the mammalian stage of Leishmania has been hampered by cost and
the time consuming effort required to accomplish it. The ability to derive transgenic Leishmania
expressing reporter genes opened up new possibilities for the development of drug screening tests.
Further developments to standardize and gather multiple informations could now be envisionned.
We will discuss on such available methodologies that could improve sensitivity, reliability, versatility
and the rapidity, of the screen based on intracellular model.
Background
Leishmania is a protozoan parasite that is responsible for
several pathologies collectively known as leishmaniasis.
According to the latest WHO, 12 million people are
affected by leishmaniasis worldwide and 2 million new
cases occur each year [1]. Moreover, the of rise Leishmani-
asis is due to multiple factors including the AIDS epi-
demic, increase of international travel, a lack of effective
vaccines, difficulties in controlling vectors, international
conflicts and the development of resistance to chemother-
apy. Methodologies that closely mimic the conditions
encountered by Leishmania are required. In this focus, we
discuss the potential application of the reporter gene tech-
nology, in multiplexing experiments, as a future strategy
for drug screening against intracellular Leishmania amas-
tigotes.
Reporter gene technology for drug screening 
against intracellular amastigotes
The term reporter gene is used to define a gene with a
readily measurable phenotype that can be distinguished
easily over a background of endogenous proteins [2]. Var-
ious recombinant parasites carrying a reporter gene either
as an episomal copy or after its integration in a defined
locus, generally the rDNA locus, is currently available. For
some of them, the capacity of these cell lines to be used for
in vitro drug screening procedure was evaluated against
axenic or intramacrophagic amastigotes (See table 1).
Autofluorescent proteins present the advantage of no
requirement in cofactors or substrates since the protein is
intrinsically fluorescent [3]. Various Leishmania  species
expressing GFP, multimeric GFP or enhanced GFP (eGFP)
were engineered [4-10]. Generally transfectants do not
express sufficient levels of fluorescence for spectrofluoro-
metric measurement on microplate. To overcome this
kind of problem a multimeric form of the GFP was engi-
neered and expressed in Leishmania  promastigotes. As
expected, parasites expressing the multimeric GFP form
bear fluorescence quantifiable in 96 wells with spec-
trofluorometric analysis [6].
Generally, methods that use catalytic reporter genes tech-
nology like luciferase, β-galactosidase,  β-lactamase are
more sensitive than methods based on fluorescent pro-
teins. Promastigotes of Leishmania expressing β-galactosi-
dase were selected and their use in drug screening
procedures evaluated [8]. β-galactosidase presents the
advantage that colorimetric detection can be performed.
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However some commonly cited drawbacks of β-galactosi-
dase include its large size (the monomer is 116 kDa) and
the endogenous expression of β-galactosidase by some
mammalian cell types including macrophages [11-13]. To
circumvent these shortcomings, a catalytic reporter system
based on β-lactamase was developed [13]. Two species of
Leishmania: Leishmania major and Leishmania amazonensis
expressing  β-lactamase were engineered and selected.
Activity of some standard antileishmanial drugs was eval-
uated on intramacrophagic amastigotes. Overall, the
results obtained demonstrate that this methodology
could be valuable for drug screening procedures [12].
Various species of parasites expressing luciferase were
recently developed and their susceptibility towards classi-
cal antileishmanial agents investigated [14-16]. The main
advantages of this technology are numerous and include
the high sensitivity of the test and the absence of back-
ground activity in the host cell. Recently, a refined work
performed by Lang and co-workers demonstrated that L.
amazonensis parasites expressing firefly luciferase could be
used to monitor Leishmania infection in real time, through
imaging analysis. They have also tested various antileish-
manial compounds and have followed their efficacy in
live cells by using imaging [17]. The advantage of this
methodology rely on the capacity to perform experiments
on live cells, making the analysis faster and more accurate
since viability of both the parasites and the host cells is
monitored.
Reporter genes present several limitations. Cross resist-
ance conferred by the presence of the antibiotic resistance
is one of them. Neomycin confers resistance toward paro-
momycin [18]. The development of method to create
defined mutants lacking selectable markers could help to
overcome this problem [19]. The way by which the
reporter gene is introduced could also have an impact on
the throughput of the screen. When reporters are part of
plasmids, the relative output of reporter may depend on
the copy number of the transfected plasmid (which vary
from cell to cell) rather than on the activity of the drug.
Secondly transforming parasites could have biological
consequences either by disrupting the genomic architec-
ture or just by the presence of the foreign reporter gene
product. Thirdly, for the β-galactosidase technology, the
reporter could have by itself some limitations (i.e sensibil-
ity, background activity from host macrophages) that
make it inaccurate for an in vitro determination of drug
activity against intracellular parasites.
Improving standardization and the effectiveness 
of drug screening by gathering multiple 
informations simultaneously
Getting information on drug activity against an intracellu-
lar organism is difficult and time consuming. The toxicity
data against the host cell must be gathered before testing
the compound against the intracellular pathogen. Hetero-
geneity in the infection rate of the host may have an influ-
ence on the compound toxicity. The kinetic activity of the
compounds may vary and have to be evaluated. A versatile
methodology allowing the investigator to quantify and
test multiple parameters of kinetic of action, drug concen-
tration and viability against both the host cells and the
intracellular amastigotes (multiplexing) could increase
the throughput of the screen. To simultaneously gather
information on the viability of the host cells and the par-
asites the use of a combination of parasites and macro-
phages expressing different reporter can now be
envisioned. To achieve this goal, reporter must use distin-
guishable signal from each other and use compatible
chemistries. Fluorophores, that emit different wave-
lengths, have been widely used to distinguish among mul-
tiple signals. Recently, there have been a growing number
of examples using luminescence for multiplexing either in
combination with: 1- other luminescent signals, 2- fluo-
rescence or 3-β-galactosidase assay [20,21]. Since the
results are expressed as a ratio between the output signal
emitted by the host cell and the one emitted by parasites,
such methodology could also help to standardize the
experiments in order to directly compare drug activity.
The usefulness of these approaches for drug screening has
to be evaluated on intracellular parasites like Leishmania
or T. cruzi. Fibroblast expressing β-galactosidase can be
purchased at the ATCC and may thus represent good can-
didates to perform preliminary experiments, on T. cruzi.
In conclusion, the capacity of multiple gene reporter tech-
nologies to be used in multiplexing experiments have to
be evaluated since they may represent valuable tools in
the field of parasitology and pharmacology.
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Table 1: Leishmania expressing reporter gene whose capacity to 
be used in vitro for drug screening procedure has been 
determined
Species Reporter gene Expression Ref
L. donovani/L. donovaniR Firefly luciferase Episomal 16
L. amazonensis Firefly luciferase Integration 17
L. infantum/L. infantum RSbIII1 Firefly luciferase Episomal 14
L. donovani GFP Episomal 7
L. donovani R2 10
L. amazonensis β-Lactamase Episomal 12
L. major
1 in vitro selected trivalent antimony resistant L. infantum. 2 Field 
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